Science Friday Folgen

Twenty years ago, scientists found that phenylephrine, listed as a decongestant in many cold medicines, didn’t work. What can you use instead? In September, an advisory committee for the Food and Drug Administration unanimously confirmed that phenylephrine—a common ingredient in cold medicines, including some types of Mucinex and Robitussin—doesn’t work.For many physicians, pharmacists, and cold-sufferers, this came as no surprise. Phenylephrine’s ineffectiveness had been an open secret in the healthcare community for decades.In 2005, Dr. Randy Hatton, clinical professor at the Pharmaceutical Outcomes and Policy Department at the University of Florida, managed the University of Florida Drug Information and Pharmacy Resource Center hotline. He often received calls from pharmacists reporting that phenylephrine-based drugs had no effect on improving colds.He came across research from Dr. Leslie Hendeles, professor emeritus of the College of Pharmacy, also at the University of Florida, from a decade prior. Dr. Hendeles had also found that the substance was ineffective. They partnered up and petitioned the FDA to publicly confirm their finding. Their collaboration was the first step toward the FDA’s recent announcement.But despite the announcement, the removal of these drugs from shelves is not guaranteed. Pharmaceutical companies are appealing the FDA’s decision, and are trying to stall an official declaration that prohibits their sale.Guest host Flora Lichtman talks with Dr. Hatton and Dr. Hendeles about the long road to the FDA’s announcement.They discuss how their research proved phenylephrine’s ineffectiveness, and which drugs people can turn to instead as cold season approaches.To stay updated on all things science, sign up for Science Friday's newsletters. Transcripts for each segment will be available the week after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

There’s a name that’s hard to escape these days, particularly if you’re in the technology world—Elon Musk. He’s involved with Tesla electric cars, home solar and battery installations, SpaceX rockets, Starlink satellites, and the company that once was known as Twitter. Woven through his array of enterprises is a mix of technical savvy, confident ego, and sometimes impulsive decision-making.Biographer Walter Isaacson has tried to sort through the competing influences behind the entrepreneur and his mercurial behavior in a recent book titled simply Elon Musk. He joins Ira to talk about the business magnate’s origins, his management style, and the incessant appetite for risk and drama that drives his successes—and, sometimes, his dramatic failures. To stay updated on all things science, sign up for Science Friday's newsletters. Transcripts for each segment will be available the week after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

RSV has reached epidemic levels in the southern US. Also, beech leaf disease is spreading rapidly in Massachusetts.RSV Drug For Infants In Short SupplyRespiratory syncytial virus, or RSV, is a common illness that—for most—looks like a common cold. But for infants, it can be an intense illness, leading to hospitalization. That’s why it was a relief for parents and physicians when an immunization drug for all infants was approved in July.However, it’s become clear the demand for the drug is greater than the supply. This week, the CDC issued an alert about the drug’s limited availability, and recommended that only infants under 6 months and those with underlying health conditions receive it until further notice. An RSV spike in the southern US has reached seasonal epidemic levels, a sign that transmission will likely climb in other areas soon.Katherine J. Wu, science writer for The Atlantic, joins guest host Flora Lichtman to chat about this story as well as mouse mummies in the Andes, Hurricane Otis defying forecasts, a secret benefit of “Asian glow,” and other big news from the week.Beech Leaf Disease Is Spreading Rapidly in MassachusettsA new tree disease has spread in forests in Massachusetts, joining invasive pests and climate change as top priorities for foresters to address.The state has found beech leaf disease in more than 90 communities since it was first discovered in the state in 2020.“Lately this has been one of our biggest concerns and my team devotes a lot of time to it. We do expect to see a lot of long-term impact and trees lost from it,” said Nicole Keleher, forest health program director at the state Department of Conservation and Recreation.Beech leaf disease is caused by an unusual parasite: a nematode, which is a microscopic roundworm, that infects the leaves and buds. Researchers believe that it may be spread by birds, insects and wind. This makes it more difficult to treat than visible insects like the emerald ash borer that can be somewhat contained by asking people not to transport wood between forests, according to Keleher.Infected leaves can develop dark patches or stripes, and often will curl up. The infection causes the tree’s leaves to fall off and can eventually starve the tree, which can die within a few years.Read the rest at sciencefriday.com.To stay updated on all things science, sign up for Science Friday's newsletters. Transcripts for each segment will be available the week after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.